The single-cell level molecular characteristics according to combination immunotherapy response of non-small cell lung cancer patients.

Non-small cell lung cancer patients finally acquire EGFR-TKI resistance. For these patients, combination immunotherapy, atezolizumab plus bevacizumab and carboplatin/paclitaxel (ABCP), was proposed as a therapy based on targetting both cancer and stromal cells. Despite of relatively good therapeutic outcome, precise mechanism was not fully understood. To dissect tumor microenvironment and regulatory mechanism involved in ABCP response, we performed scRNA-seq analysis from patients to receive ABCP. Single-cell transcriptome analysis was performed using malignant cells acquired from pleural effusion samples of seven patients before treatment. Cellular characteristics according to therapeutic response were dissected.